← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Apt Therapeutics, Inc.
Saint Louis, MO
$22,171,534
Total funding
31
Grants
Funding over time
peak $2.3M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,171,534 · 31
By mechanism
R44$13,126,895 · 7
R43$6,045,338 · 23
SB1$2,999,301 · 1
Investigators at Apt Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Human Apyrase Therapy for Acute Ischemic Stroke$1,768,629
SB1 · FY2017 · NS
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction$1,717,926
R44 · FY2025 · HL
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction$1,582,022
R44 · FY2023 · HL
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction$1,360,862
R44 · FY2024 · HL
Immunomodulatory Therapy for Neuropathic Pain$996,399
R44 · FY2021 · NS
Human Apyrase Therapy for Acute Ischemic Stroke$968,157
SB1 · FY2016 · NS
Immunomodulatory Therapy for Neuropathic Pain$922,476
R44 · FY2022 · NS
Antithrombotic Therapy with No Bleeding Risk for PCI$878,319
R44 · FY2018 · HL
Adjunctive Use of Apyrase to Fibrinolytic Therapy$729,640
R44 · FY2012 · HL
Antithrombotic Therapy with No Bleeding Risk for PCI$723,518
R44 · FY2019 · HL
Combination Treatment of tPA and Apyrase for Stroke$612,233
R44 · FY2010 · NS
Adjunctive Use of Apyrase to Fibrinolytic Therapy$577,816
R44 · FY2013 · HL
Immunomodulatory Therapy for Neuropathic Pain$501,320
R44 · FY2023 · NS
Combination Treatment of tPA and Apyrase for Stroke$494,921
R44 · FY2011 · NS
Antithrombotic Effects of Optimized Human Apyrase$453,690
R44 · FY2007 · HL
Apyrase to treat ischemia/reperfusion injury during lung transplantation$439,052
R44 · FY2010 · HL
Apyrase to treat ischemia/reperfusion injury during lung transplantation$400,811
R44 · FY2009 · HL
Combination treatment with tPA and IL2 analog for Stroke$344,933
R43 · FY2019 · NS
Prevention of Post-MI Heart Failure with Immunomodulatory Therapy$337,602
R43 · FY2018 · HL
Antithrombotic Effects of Optimized Human Apyrase$336,745
R44 · FY2006 · HL